

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT 1638  
Attorney Docket No.: 023070-114510US  
Client Reference No.: 2001-083-1

Commissioner for Patents  
Washington, D.C. 20231

On:

April 8, 2003

TOWNSEND and TOWNSEND and CREW LLP

By:

Mark T. DAVIS

PHS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

McDonald, Karen A.  
Jackman, Alan P.

Application No.: 09/992,845

Filed: November 14, 2001

For: PROCESS FOR SCALED-UP  
PRODUCTION OF RECOMBINANT  
PROTEINS USING TRANSGENIC  
PLANT SUSPENSION CULTURES

Examiner: Not Yet Assigned

Art Unit: 1638

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER 37  
CFR §1.97 and §1.98

Commissioner for Patents  
Washington, D.C. 20231

Sir:

RECEIVED  
APR 15 2003  
TECH CENTER 1600/2900

The references cited on attached form PTO/SB/08A are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the Search/Examination report corresponding to the PCT application.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.


However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Beth L. Kelly  
Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
MTD:mtd  
SF 1447275 v1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form PTO/SB/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	09/992,845
Filing Date	November 14, 2001
First Named Inventor	McDonald, Karen A. , et. al.
Art Unit	1638
Examiner Name	Unassigned
Attorney Docket Number	02307O-114510US

**U.S. PATENT DOCUMENTS**

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-4,064,015	12/20/1977	Nyiri et al.	
	AB	US-5,693,506	12/02/1997	Rodriguez	

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AC	van Lier et al., "Long-term semi-continuous production of recombinant baculovirus protein in a repeated (fed-) batch two-stage reactor system", Enzyme and Microbial Technology 18:460-466 (1996).	
	AD	Glick et al., "Molecular Biotechnology: Principles and Applications of Recombinant DNA", ASM Press, Washington, D.C., page 312, lines 1-8, (1994).	

**RECEIVED**

APR 15 2003

TECH CENTER 1600/2900

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
------------------------	--------------------------	---	----------------

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1447275 v1